Current ratio of Coherus BioSciences, Inc.
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non?small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohn's Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
|ADVM Adverum Biotechnologies, Inc.||NASDAQ > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||178.78|
|SNDX Syndax Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||189.52|
|SCYX SCYNEXIS, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||192.25|
|ASMB Assembly Biosciences, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||200.56|
|TPHS Trinity Place Holdings Inc.||NYSEMKT > Consumer Services > Building operators||201.35|
|SYRS Syros Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||229.04|
|CHRS Coherus BioSciences, Inc.||NASDAQ > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||238.12|
|LJPC La Jolla Pharmaceutical Company||NASDAQ > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||8,824.21|
|RARE Ultragenyx Pharmaceutical Inc.||NASDAQ > Health Care > Major Pharmaceuticals||10,880.38|
|RIOT Riot Blockchain, Inc||NASDAQ > Health Care > Biotechnology: In Vitro & In Vivo Diagnostic Substances||14,181.75|
|ADMS Adamas Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||22,090.90|
|GLYC GlycoMimetics, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||26,375.14|
|PRKR ParkerVision, Inc.||NASDAQ > Technology > Radio And Television Broadcasting And Communications Equipment||91,633.80|